लैपाटिनिब और पाज़ोपैनिब का इंटरैक्शन

Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP.

Clinical trials of VOTRIENT in combination with pemetrexed and lapatinib were terminated early due to increased toxicity and mortality.

Transporters Coadministration of strong inhibitors of P-gp or BCRP may increase pazopanib concentrations.

Consider selection of alternative concomitant medicinal products with no or minimal potential to inhibit P-gp or BCRP.